Biotech Values

[DewDiligence]

WVE—WaVe’s claim—something it’ll have to prove—is that chirality is important for RNA drugs… Current techniques for synthesizing these molecules don’t control for [chirality], so they produce a mixture of thousands of different versions of a would-be drug—each with “unique pharmacology,” [CEO] Bolno says.

…Bolno says this is because the issue was ”not possible to address” before WaVe came along. But the question is whether it matters. WaVe contends that it does, and that the company has developed a way to control the chirality of the RNAs it produces.

I’m somewhat skeptical of these lofty claims due to the exponential number of molecular variations relative to the number of chiral centers.